$1.5M Award in Child Tardive Dyskinesia Malpractice Lawsuit

3
512

A Chicago jury awarded $1.5 million to an autistic child who developed irreversible and disabling tardive dyskinesia and tardive akathisia while treated with Risperdal, followed by Zyprexa.  The boy had been diagnosed with autism as a child and started on SSRI antidepressants by the age of seven, which according to expert witness Peter Breggin caused his mental condition and behavior to deteriorate.

Article →

Previous articleThe Origins of Mental Health Services
Next articleSSRI ‘Indication Creep’ Relies on Negligent Doctors
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected].

3 COMMENTS

  1. If only the justice could be for everybody and not just those who can find a good lawyer at the right time. In any case, no amount of money is going to help to improve his life and is probably going to just wind up in the pockets of “caregivers” who force him back onto those drugs in the future.

    Report comment

  2. I think this is a promising sign. But I, too, wish ALL doctors who misdiagnosed adverse reactions to antidepressants, then rendered patients senseless with antipsychotics, would be forced to pay their patients. It’s malpractice, torture, and plain evil.

    Report comment

LEAVE A REPLY